Concepedia

Zelei Yu

ZY

Statistics

Publications

5

Citations

175

H-Index

5

Active since

2020

Affiliations

Fujian Medical University(Current)

Zelei Yu is an author at Fujian Medical University specializing in drug discovery, molecular oncology, and parp inhibition.

Publications per year

2020–2022

5

Publications

5

A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer

Ge Li, Shanshan Lin, Zelei Yu et al. · Biochemical Pharmacology · 2022 · 63 citations

, , +14

Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer

Quanyu Liu, Guihui Tu, Yan Hu et al. · European Journal of Medicinal Chemistry · 2021 · 37 citations · Full text

, , +11

Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities

Shanshan Lin, Lingyu Zhang, Xiao Zhang et al. · Bioorganic & Medicinal Chemistry · 2020 · 32 citations · Full text

, , +13

Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS/STING immunity pathway combined with daunorubicin

Shanshan Lin, Guihui Tu, Zelei Yu et al. · Bioorganic & Medicinal Chemistry · 2022 · 22 citations

, , +9

Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers

Shanshan Lin, Xiaozhen Zhang, Zelei Yu et al. · Bioorganic & Medicinal Chemistry · 2022 · 21 citations

, , +11

1–5 of 5